Developing targeted nanoparticle therapies for lupus nephritis
Official title: Core B - BWH Nanoparticle Core
Funded at Beth Israel Deaconess Medical Center · NIH-11046580 · Data updated 2026-11-12
This study is exploring new tiny treatments that can help people with lupus nephritis by delivering medicine directly to the kidneys, aiming to improve how well the treatment works while reducing side effects.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $352,599 |
| NIH project number | 5P01AI179405-02 |
| Project ID | NIH-11046580 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with lupus nephritis who are seeking more effective treatment options.
✕Less likely to help
Patients with lupus nephritis who are not responsive to immune therapeutics or those with contraindications to nanoparticle therapies may not benefit from this research.
What this research studies
This research focuses on creating advanced nanoparticle-based therapies aimed at improving treatment outcomes for patients with lupus nephritis (LN). By utilizing nanotechnology, the project seeks to enhance the delivery of immune therapeutics directly to the kidneys, where they are most needed, while minimizing systemic side effects. The approach involves targeting newly formed blood vessels in the kidneys to ensure that the therapeutic agents effectively suppress harmful immune responses. This innovative method aims to address the significant challenges and complications associated with current treatment regimens.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for lupus nephritis, reducing complications and improving patient outcomes.
How similar studies have gone: While there has been significant success in using nanotechnology for cancer treatments, the application of nanoparticle therapies specifically for lupus nephritis is still a novel approach.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Abdi, Reza — Beth Israel Deaconess Medical Center
- Study coordinator: Abdi, Reza
Related research
Other NIH-funded projects on the same topics.
-
SATURN MRI ancillary study: statins after intracerebral hemorrhage and brain MRI markers
This study looks at what happens to brain MRI markers and health outcomes when people with a specific type of brain bleed continue or stop taking statins.
-
Statin use after brain bleed MRI study in ICH patients (SATURN MRI) Ancillary Study
This project tests whether continuing or stopping statin therapy after an intracerebral hemorrhage affects brain changes seen on MRI and related health outcomes in people with lobar ICH.
-
Statin use after brain bleed: SATURN MRI ancillary study
This project tests whether continuing statin medicines after a brain bleed (lobar intracerebral hemorrhage) affects new brain blood vessel findings and long-term health.
-
XenCAT: Single Cell Atlas for Xenopus
Aims to map gene activity at the single-cell level in Xenopus to help understand how cells develop and how this relates to human disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.